Adherence to treatment in systemic lupus erythematosus patients
Adherence to treatment in systemic lupus erythematosus patients
复制标题
DOI：
10.1016/j.berh.2013.07.001
复制
发表时间：
2013-06-01
影响因子：
5.2
通讯作者：
Piette, Jean-Charles
中科院分区：
文献类型：
--
作者：
Costedoat-Chalumeau, Nathalie;Pouchot, Jacques;Piette, Jean-Charles
依从性被定义为“一个人的行为符合医疗或健康建议的程度”。对于包括系统性红斑狼疮（SLE）在内的慢性疾病患者来说，治疗方案的依从性差是一个常见且昂贵的问题，并与更高的发作、发病率、住院和肾脏预后差的风险相关。对大多数患者来说，不坚持治疗是多因素的，并根据无意或有意的模式而变化。根据评估方法的不同，SLE患者的不依从率从3%到76%不等，这些评估方法都有局限性。事实上，对治疗方案的不良依从性很难评估。两项研究表明，血液中检测不到的羟氯喹（HCQ）浓度可能是SLE患者不依从性的一个简单、客观和可靠的标志。对不依从的准确诊断可以防止人们错误地将疾病表现解释为缺乏反应。这样就可以避免不必要的甚至危险的治疗升级。(C) 2013 Elsevier Ltd.版权所有。
Adherence is defined as "the extent to which a person's behaviour coincides with medical or health advice." Poor adherence to therapeutic regimens is a common and expensive problem in patients with chronic diseases including systemic lupus erythematosus (SLE) and is associated with a higher risk of flares, morbidity, hospitalisations and poor renal outcome. Non-adherence to the treatment is multifactorial for most patients and varies according to unintentional or intentional patterns. The rates of non-adherence in SLE patients range from 3% to 76% depending on the assessment methods, which are all subject to limitations. Indeed, poor adherence to therapeutic regimens is difficult to evaluate. Two studies have shown that undetectable blood hydroxychloroquine (HCQ) concentration may be a simple, objective and reliable marker of non-adherence in SLE patients. The accurate diagnosis of non-adherence may prevent one from incorrectly interpreting disease manifestations as a lack of response. It may then avoid an unnecessary or even dangerous treatment escalation. (C) 2013 Elsevier Ltd. All rights reserved.